GeoVax Labs' Q1 2025: Key Contradictions in Vaccine Manufacturing and Trial Timelines

Mpox vaccine manufacturing and government support, phase 2 trial timelines for immunocompromised patients, government engagement and communication, manufacturing timeline and capacity, and focus on immunocompromised populations are the key contradictions discussed in GeoVax Labs' latest 2025Q1 earnings call.



BARDA Contract Termination:
- GeoVax Labs received a Stop Work Order for the BARDA Project NextGen program, with an anticipated financial impact of less than $750,000 annually.
- The termination was due to government efficiency efforts and did not imply concerns about the safety or efficacy of the products.

CMV04S1 Clinical Trials:
- GeoVax continues investor-initiated Phase II trials for CMV04S1, focusing on immunocompromised patient populations.
- The trials, unaffected by the BARDA termination, aim to demonstrate the superior value of CMV04S1 among immunocompromised patients.

GEO-MVA Progress:
- cGMP production and quality release of the clinical batch of GEO-MVA is complete, with sufficient product for clinical evaluation and additional use.
- GEO-MVA is expected to provide an advantage in production and expand the global supply of MVA vaccines, addressing epidemic outbreaks and stockpile opportunities.

Financial Results and R&D Expenses:
- Revenues associated with the BARDA contract were $1.6 million in Q1 2025, with research and development expenses increasing by $1 million or 21%.
- The increase in R&D expenses is attributed to costs related to the BARDA contract and programs for Gedeptin and GEO-MVA.